1-4 of 4
Dongmei Ji, MD
Close
Sort by
Journal Articles

Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas

Junning Cao, Zhiming Li, MD PhD, Jianfeng Zhou, MD PhD, Dongmei Ji, MD PhD, Weina Shen, PhD, Peng Sun, MD, Yu Wang, MD, Dengju Li, MD, Zhenya Hong, MDPhD, Gaoxiang Wang, MDPhD, Xianlin Duan, MD, Chen Yu, MD, Yu Cai, PhD, Weiguo Su, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38.
https://doi.org/10.1182/blood-2020-136013
Published: 2020
Journal Articles

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Yuankai Shi, MD, Lin Gui, MD, Junning Cao, MD, Huilai Zhang, MD, Jun Zhu, MD PhD, Dongmei Ji, MD PhD, Qian Fan, MD, Yuqin Song, MD PhD, Weina Shen, MM, Guiying Bai, MM, Ming-Zhe Han, MD, Shiyu Jiang
Journal: Blood
Blood (2019) 134 (Supplement_1): 2840.
https://doi.org/10.1182/blood-2019-128078
Published: 2019
Journal Articles

Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Jun Zhu, MD PhD, Junning Cao, MD, Lugui Qiu, MD PhD, Junyuan Qi, MD, Yuqin Song, MD PhD, Meifeng Tu, MD PhD, Dongmei Ji, MD PhD, Weina Shen, MD, Mingyuan Sun, MD, Ye Hua, MD, Chen Yang, MD, Chen Yu, MD, Jian Wang, PhD, Guangxiu Dai, PhD, Weiguo Su, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5324.
https://doi.org/10.1182/blood-2018-99-111648
Published: 2018
Journal Articles

Phase Ib Studies of Benegrastim in Chinese Women with Breast Cancer Receiving Myelotoxic Chemotherapy

Junning Cao, MD, Zhongyu Yuan, MD, Cheng Huang, MD, Dongmei Ji, MD, Rujun Peng, MD, Xiaoqiang Yan, PhD, Tom Tang, MD
Journal: Blood
Blood (2015) 126 (23): 4601.
https://doi.org/10.1182/blood.V126.23.4601.4601
Published: 2015